Landos Biopharma, Inc.

LABPNASDAQHealthcare

$22.93

+$0.13(+0.57%)

Market Cap$71675511

P/E Ratio—

52W High$22.94

52W Low$3.145

Avg Volume26K

Open$22.93

Beta0.14

Free Cash Flow Financials Revenue

Landos Biopharma, Inc. (LABP) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LABP · free cash flow · updated Jun 9, 2026

Core FCF metrics

LABP · FCF · TTM · margin & CAGR

Free cash flow was −$20.5M for FY2023 (fiscal year ending 2023-12-31), up 55.3% year-over-year

FY2023 Free Cash Flow−$20.5M▲ +55.3% YoY

Trailing 12M (TTM)−$20.8Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LABP · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2023Latest−$20.5M(0M)−$20.5M▲ +55.3%—

FY2022−$45.8M(0M)−$45.8M▼ 66.5%—

FY2021−$27.1M(0M)−$27.5M▼ 18.8%-152.8%

FY2020−$23.0M(0M)−$23.1M▼ 130.7%—

FY2019−$9.9M(0M)−$10.0M▼ 44.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LABP · P/FCF · FCF yield · FCF per share

Landos Biopharma, Inc. (LABP) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2023 · 2023-12-31

Cash flow statement summary

LABP · cash flow statement · operating / investing / financing

For FY2023, Landos Biopharma, Inc. generated −$20.5M in operating cash flow and spent 0M in capital expenditures, yielding −$20.5M in free cash flow.

Operating Activities

−$20.5M

Cash from core business operations

2023-12-31

Investing Activities

+$7.8M

CapEx, acquisitions & investments

2023-12-31

Financing Activities

+$13.6M

Buybacks, dividends & debt

2023-12-31

FCF FormulaOperating CF (−$20.5M) − |CapEx| (0M) = FCF (−$20.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LABP vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Landos Biopharma, Inc.YOU

LABP

−$20.5M+55.3%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Landos Biopharma, Inc. (LABP) reported free cash flow of −$20.5M for FY2023 (fiscal year ending 2023-12-31), up 55.3% year-over-year.

Landos Biopharma, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 6 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LABP free cash flow · 8 questions

Landos Biopharma, Inc. free cash flow was −$20.5M for FY2023, up 55.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$20.8M.

LABP free cash flowLABP FCFLABP FCF 2023LABP free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Landos Biopharma, Inc. · Landos Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026